Remodulin — Cost of Sales
United Therapeutics Remodulin — Cost of Sales increased by 98.8% to $16.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 16.7%, from $13.80M to $16.10M. Over 4 years (FY 2021 to FY 2025), Remodulin — Cost of Sales shows an upward trend with a 6.8% CAGR. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
How to read this metric
An increase relative to revenue may signal rising manufacturing costs or supply chain inefficiencies, while a decrease suggests improved production economies of scale.
Detailed definition
Includes the direct costs associated with the manufacturing, packaging, and distribution of a specific pharmaceutical pr...
Peer comparison
Comparable to 'Cost of Goods Sold' (COGS) for specific product lines in the life sciences sector.
uthr_segment_remodulin_cost_of_salesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $8.40M | $6.90M | $14.40M | $7.20M | $8.60M | $7.50M | $10.70M | $6.90M | $7.30M | $11.80M | $12.20M | $7.90M | $12.80M | $13.30M | $13.40M | $13.80M | $14.30M | $13.10M | $8.10M | $16.10M |
| QoQ Change | — | -17.9% | +108.7% | -50.0% | +19.4% | -12.8% | +42.7% | -35.5% | +5.8% | +61.6% | +3.4% | -35.2% | +62.0% | +3.9% | +0.8% | +3.0% | +3.6% | -8.4% | -38.2% | +98.8% |
| YoY Change | — | — | — | — | +2.4% | +8.7% | -25.7% | -4.2% | -15.1% | +57.3% | +14.0% | +14.5% | +75.3% | +12.7% | +9.8% | +74.7% | +11.7% | -1.5% | -39.6% | +16.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is United Therapeutics's remodulin — cost of sales?
- United Therapeutics (UTHR) reported remodulin — cost of sales of $16.10M in Q1 2026.
- How has United Therapeutics's remodulin — cost of sales changed year-over-year?
- United Therapeutics's remodulin — cost of sales increased by 16.7% year-over-year, from $13.80M to $16.10M.
- What is the long-term trend for United Therapeutics's remodulin — cost of sales?
- Over 4 years (2021 to 2025), United Therapeutics's remodulin — cost of sales has grown at a 6.8% compound annual growth rate (CAGR), from $37.90M to $49.30M.
- What does remodulin — cost of sales mean?
- The direct costs incurred to produce and deliver a specific drug to market.